Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

Autor: Christa Babst, Thomas Amiel, Tobias Maurer, Sophie Knipper, Lukas Lunger, Robert Tauber, Margitta Retz, Kathleen Herkommer, Matthias Eiber, Gunhild von Amsberg, Markus Graefen, Juergen Gschwend, Thomas Steuber, Matthias Heck

Publikováno v: Asian Journal of Urology, Vol 9, Iss 1, Pp 69-74 (2022)

Objective: Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we ex

Externí odkaz: https://doaj.org/article/977dfb82a9bf40beb8784c23aa58c102

MP67-13 RELATIONSHIP BETWEEN FRAILTY AND MENTAL HEALTH AND QUALITY OF LIFE IN LONG-TERM PROSTATE CANCER SURVIVORS AFTER RADICAL PROSTATECTOMY

Autor: Kathleen Herkommer, Valentin Meissner, Lukas Lunger, Kolja Imhof, Matthias Jahnen, Donna Ankerst, Andreas Dinkel, Stefan Schiele, Juergen Gschwend

Publikováno v: Journal of Urology. 209

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9762a67e7d38df93cec8301bc65cfff1
https://doi.org/10.1097/ju.0000000000003330.13

Additional file 3: of Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer

Autor: Zhichao Tong, Sathe, Anuja, Ebner, Benedikt, Qi, Pan, Veltkamp, Christian, Juergen Gschwend, Holm, Per, Nawroth, Roman

Figure S3. Effects of combination therapies on cell cycle progression, caspase3/7 activity and long-term synergy measurement on RT112. (a) Cell cycle progression was analyzed after 72 h of treatment. (b) Caspase3/7 activity was measured and normalize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce46523f77e6a791cb59faf3a0b45f0

Additional file 1 of Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer

Autor: Zhichao Tong, Sathe, Anuja, Ebner, Benedikt, Qi, Pan, Veltkamp, Christian, Juergen Gschwend, Holm, Per, Nawroth, Roman

Figure S1. Characterization of T24 SAM clones and quality control of NGS data. (a) Expression of dCas9 and MS2-P65-HSF1 activation helper in T24 SAM clones. (b) Response of T24WT and T24 SAM2 cells to Palbociclib were evaluated by CTB assay. (c) Expr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c463d9c87ff654a3dd5f67d55b30c8f

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Autor: Michaelson MD; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Stephane Oudard, George Pompidou European Hospital, Rene Descartes University, Paris; Nadine Houede, Institut Bergonie, Bordeaux; Tristan Maurina, CHU de Besançon, Hôpital Jean Minjoz, Besançon, France; Yen-Chuan Ou, Taichung Veterans General Hospital, Taichung, Taiwan; Lisa Sengeløv, Herlev Hospital, Herlev; Gedske Daugaard, Rigshospitalet, Copenhagen, Denmark; Fred Saad, University of Montreal, Montreal, Canada; Peter Ostler, Mount Vernon Hospital, Northwood, Middlesex; Robert Jones, Beatson West of Scotland Cancer Centre, Glasgow; Amit Bahl, Bristol Haematology and Oncology Centre, Bristol, UK; Arnulf Stenzl, Eberhard-Karls-University Medical School, Tübingen; Juergen Gschwend, Technical University of Munich, Munich, Germany; Fredrik Laestadius and Anders Ullèn, Karolinska University Hospital, Stockholm, Sweden; Daniel Castellano, I_12 Research Institute, University Hospital 12 de Octubre, Madrid, Spain; Edna Chow Maneval, Shaw-Ling Wang, and Isan Chen, Pfizer Oncology, La Jolla, CA; and Maria Jose Lechuga and Jolanda Paolini, Pfizer Oncology, Milan, Italy., Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jan 10; Vol. 32 (2), pp. 76-82. Date of Electronic Publication: 2013 Dec 09.